Transcription Factor AP-2beta (TFAP2B) in development, differentiation and tumorigenesis
Cet article passe en revue les connaissances concernant le rôle du facteur de transcription AP-2 bêta dans le développement et la différenciation des tissus ainsi que dans la tumorigenèse
To date, the AP‐2 family of transcription factors comprises five members. TFAP2B/AP‐2
β was first described in 1995. Several studies indicate a critical role of AP
‐2
β in the development of tissues and organs of ectodermal, neuroectodermal and also mesodermal origin. Germline
‐mutation of TFAP2B is known to cause the Char‐Syndrome, an autosomal dominant disorder characterized by facial dysmorphism, patent ductus arteriosus and anatomical abnormalities of the fifth digit. Furthermore, single nucleotide polymorphisms in TFAP2B were linked to obesity and specific personality traits. In neoplasias AP‐2
β was first described in alveolar rhabdomyosarcoma. Immunohistochemical staining of AP
‐2
β is a recommended ancillary test for the histopathological diagnosis of this uncommon childhood malignancy. In neuroblastoma AP
‐2
β supports noradrenergic differentiation. Recently, the function of AP
‐2
β in breast cancer (BC) has gained in interest. AP
‐2
β is associated with the lobular BC subtype. Moreover, AP
‐2
β controls BC cell proliferation and has a prognostic impact in patients with BC. This review provides a comprehensive overview of the current knowledge about AP
‐2
β and its function in organ development, differentiation and tumorigenesis.
International Journal of Cancer , résumé, 2021